Marinus Pharmaceuticals, Inc. (MRNS) - EV/EBITDA Multiple
Marinus Pharmaceuticals (MRNS) is integrating environmental principles into the development of neurological drugs, strictly adhering to bioethics and waste disposal regulations. However, geopolitical tensions and sanctions are hindering international trials and disrupting the supply of biomaterials. This chart illustrates a market EV/EBITDA multiple of , which is critical given the business's heavy reliance on the sales of a single anticonvulsant drug and the necessity for stringent liquidity control.
Analytical breakdowns for Marinus Pharmaceuticals
- market price and analyst price targets:
- market capitalization indicators:
- issuer book value statistics:
- company liabilities and liquidity data:
Debt to Equity Marinus Pharmaceuticals|MRNS - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Ratio Marinus Pharmaceuticals, Inc.|MRNS - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Marinus Pharma|MRNS - Long-Term Liabilities|Company Short-Term Debts Marinus Pharmaceuticals|Quick Ratio marinuspharma.com
- business earnings and investment ratios data:
MRNS - Net Profit|Expected Profit Marinus Pharmaceuticals|MRNS - Company Value to Net Income|Future Price to Earnings Marinus Pharmaceuticals|MRNS - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Marinus Pharma|MRNS - Operating profit EBITDA|Net earnings per share (EPS TTM) Marinus Pharmaceuticals|MRNS - Net earnings per share for the last 12 months|Quarterly EPS earnings growth marinuspharma.com|MRNS - Earnings per share growth rate in current year|Expected earnings per share growth for next year Marinus Pharmaceuticals
- sales and revenue indicators:
Summary company analysis:MRNS (Marinus)
When screening issuer reliability, it is essential to evaluate the business value accounting for net debt and tax liabilities. This indicator relates the enterprise value (EV) to earnings before interest, taxes, depreciation, and amortization (EBITDA), stripping the valuation of capital structure influence. The historical EV/EBITDA trend for Marinus Pharmaceuticals (MRNS) will demonstrate how effectively the R&D portfolio restructuring and the commercialization of the core product translate into actual market value.
Direct competitors
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Biogen Corp BIIB|Business Value to Operating Income Before Depreciation NBIX|Regencell Bioscience - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio axsome.com AXSM|ACADIA Pharmaceuticals Inc. (ACAD) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation XENE|Enterprise Value to EBITDA Ratio VKTX|EV/EBITDA Multiple Supernus Corp|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Catalyst Pharmaceuticals (CPRX)|Total Company Value to Operating Income Before Depreciation Ratio denalitherapeutics.com|Harmony Biosciences Holdings, Inc. - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation BHVN|AMLX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio TRVI|PRAX: EV/EBITDA Multiple|anavex.com - Business Value to Operating Income Before Depreciation|CBLL (CeriBell) - EV/EBITDA Multiple|EV/EBITDA Multiple Prothena Corporation PLC|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Alector, Inc. (ALEC)|ANNX (Annexon Biosciences Inc.) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Omeros OMER|NGNE - Enterprise Value to EBITDA Ratio|AC Immune SA - EV/EBITDA Multiple|VYGR - EV/EBITDA Multiple|NMRA: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Scilex Holding Company, Inc.|TVGN (Tevogen Bio Holdings) - EV/EBITDA Multiple|Company Value to EBITDA Alpha Cognition Corp ACOG|Enterprise Value to EBITDA Ratio CGTX (Cognition Therapeutics, Inc.)|EV/EBITDA Multiple Inhibikase Therapeutics Inc (IKT)|Cassava - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio ASRT (Assertio Holdings)|Coya - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Vistagen Therapeutics VTGN|OVID: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Acumen Pharmaceuticals Inc.|CRVO (CervoMed Inc) - EV/EBITDA Multiple|EV/EBITDA Multiple Alterity Therapeutics Ltd|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Clene Inc. (CLNN)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization PEPG (pepgen.com)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Jupiter Neurosciences JUNS|Total Company Value to Operating Income Before Depreciation Ratio Relmada Therapeutics Inc (RLMD)|ANVS - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Grace Therapeutics, Inc. (GRCE) - Enterprise Value to EBITDA Ratio|Firefly Neuroscience, Inc (AIFF) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Klotho Neurosciences - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NeuroSense Therapeutics Ltd|Enterprise Value to Operating Income Before Depreciation RVPH (Reviva Pharmaceuticals Holdings Inc.)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization MetaVia Inc (MTVA)|Total Company Value to Operating Income Before Depreciation Ratio NeurAxis Inc|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Helius Medical Technologies HSDT|PASG: Enterprise Value to Operating Income Before Depreciation|Neuphoria - EV/EBITDA Multiple|Company Value to EBITDA Minerva Neurosciences Inc|ATHA (Athira) - Enterprise Value to EBITDA Ratio|Addex (ADXN) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Alzamend Neuro Inc.|CYCN: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Protagenic Therapeutics (PTIX)|KTTA - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Cortigent CRGT|ATXI - Enterprise Value to EBITDA Ratio|Brainstorm Cell - EV/EBITDA Multiple|CARA - EV/EBITDA Multiple|Chromocell Therapeutics Corp. (CHRO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Eliem Therapeutics Inc. - Business Value to Operating Income Before Depreciation|ITCI (Intra-Cellular Therapies Inc.) - EV/EBITDA Multiple|Longboard (LBPH) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NKGen Biotech, Inc. (NKGN)|neurobopharma.com - Enterprise Value to Operating Income Before Depreciation|Sage Therapeutics - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Synaptogenix Inc. SNPX|TRVN - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio Vigil Neuroscience VIGL|WENA (Anew Medical, Inc.) - Enterprise Value to EBITDA Ratio|cerevel.com - Business Value to Operating Income Before Depreciation
